Skip Navigation LinksHome > Public & Participants > Research Studies  
 

Clinical Research Studies


Studies Currently Open for Enrollment



Noble - A New Study for People with Mild to Moderate Alzheimer's Disease

Click here for more information

A4 – Anti Amyloid in Aysymptomatic Alzheimer’s Disease

Click here for more information

DIAN Study

Click here for more information

Research suggests that brain changes may occur years before actual Alzheimer’s symptoms are detected. The major goal of DIAN is to study these changes in people who carry an Alzheimer’s disease mutation to determine how the disease process develops before there are any symptoms. Ultimately, knowledge gained from DIAN may lead to tests that detect people who still are normal but are at very high risk of developing dementia caused by Alzheimer’s disease. All DIAN participants will be members of families with dominantly inherited Alzheimer’s disease caused by a known mutation.


Studies That Will Be Open for Enrollment Soon


CONNECT Study

Click here for more information

SNIFF – the Study of Nasal Insulin to Fight Forgetfulness

Click here for more information


Ongoing Studies Closed for Enrollment




Closed Studies



Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI 2)

Click here for more information

Building on the momentum of the previous phases of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), this study focuses on participants with early mild cognitive impairment, late mild cognitive impairment, early to moderate Alzheimer’s disease and people with no memory complaints.

Resveratrol

Click here for more information

Nerve Growth Factor (NGF) Study

Click here for more information

A Phase II clinical study of Ceregene's CERE-110, a gene therapy product designed to deliver nerve growth factor (NGF) to the brain for the treatment of Alzheimer's disease (AD) is currently underway.


Home-Based Assessments (HBA) Study

Click here for more information

This study will evaluate three methods of performing home-based assessments in an Alzheimer's Disease (AD) prevention trial.


Alzheimer's Disease Neuroimaging Initiative (ADNI) Study

Click here for more information

This study is a large five year (we began on Oct 1 2004) research project to study the rate of change of cognition, function, brain structure, function, and biomarkers in 200 elderly controls, 400 subjects with mild cognitive impairment, and 200 with Alzheimer's disease.


Gammaglobulin Alzheimer’s Partnership (GAP/IVIg) Study

Click here for more information

Intravenous Immune Globulin (IVIg) has been approved and used successfully for over 20 years to treat a variety of autoimmune and immunodeficient diseases. Because it contains anti-amyloid antibodies IVIg is being investigated in a Phase III study as a treatment for Alzheimer's disease.


Docosahexaenoic Acid (DHA) Study

Click here for more information

A Randomized Double-Blind Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer's Disease.


Valproate Neuroprotection (VN) Study

Click here for more information

Primary Objective:To determine whether chronic valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in their illness.


RAGE Inhibitor (RI) Study

Click here for more information

Researchers are participating in a new nationwide study that will test an experimental treatment to target the source of the disease. The experimental drug may block a critical pathway in AD that causes damage to the nerve cells in the brain. Participants will receive either the active study drug or placebo (inactive pill). All participants will be monitored carefully by a team of doctors and nurses at the research clinic throughout the study.


Huperzine A (HU) Study

Click here for more information

A multicenter, double-blind, placebo-controlled therapeutic trial to determine whether natural huperzine A improves cognitive function in Alzheimer's Disease.